Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Panel Will Have To Resolve Bleeding Risk With Merck’s Vorapaxar

This article was originally published in The Pink Sheet Daily

Executive Summary

Novel antiplatelet product has suffered from excess bleeding rates in clinical trials and is searching for an appropriate patient population, after initial hopes of being a blockbuster.


Related Content

“Use With Caution” Isn’t Specific Enough For Labeling, FDA Tells Merck At Vorapaxar Panel
FDA Reviewers Say Vorapaxar Approvable, But Question Study Changes
Bleeding Rates In TRA-2P Further Dim Outlook For Merck’s Vorapaxar
Brilinta Approval Shows AstraZeneca's Success With Aspirin Theory, But Can It Change The Market?
Intracranial Hemorrhage The Culprit In Merck's Vorapaxar Trial
Merck R&D: A Jam-Packed Pipeline But Much Of It Wait-And-See
Effient Approval Shows Mark Of FDA Controls


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts